Medical Costs Associated with Insomnia Treatment with Suvorexant Monotherapy in Japan: Results from a Retrospective Cohort Study Using a Large-Scale Claims Database.

ABSTRACT:

Background

The association of insomnia treatment with medical costs is not well characterized in Japan, despite the high economic burden of insomnia.

Objective

The aim of this study was to investigate the impact of suvorexant, the first dual orexin receptor antagonist, on direct medical costs in insomnia patients.

Patients and methods

This retrospective cohort study, conducted using a large-scale claims database, included Japanese patients with diagnosed insomnia receiving suvorexant who were treatment naïve or treatment switchers (pre-treated with a different hypnotic and switched to suvorexant). Total medical costs were estimated for 1 year before and after suvorexant initiation; p-values were calculated for the difference in costs.

Results

Of the 1730 patien

SUBMITTER: Uchiyama M 

PROVIDER: S-EPMC9114234 | biostudies-literature | 2022 Jun

REPOSITORIES: biostudies-literature